Welcome Guest
Home > Clinical Lymphoma & Myeloma > Volume 1 | Supplement 1

Table of Contents

Volume 1 | Supplement 1

Publication Date: November 2000
  • Abstract Abstract
  • Full Text No Access
  • Full Text Pay-Per View
  • Full Text Full Text
  • Add to Cart Add to Cart


Introduction
Page Number of this Article in the Print Version
S7		 Two Novel Therapies for the Treatment of Cutaneous T-Cell Lymphoma
C. Frederick LeMaistre
  • Abstract
  • No Access
  • Add to Cart
Contributions
Page Number of this Article in the Print Version
S9-S14		 An Oncologist’s Approach to Therapy for Cutaneous T-Cell Lymphoma
Francine M. Foss
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S15-S20		 Treatment of Cutaneous T-Cell Lymphoma from a Dermatologist’s Perspective
Madeleine Duvic
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S21-S25		 Cutaneous T-Cell Lymphomas: Prognosis and Quality-of-Life Issues
Reinhard Dummer, Monika Hess-Schmid, Günter Burg
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S27-S31		 DAB389IL-2 (Denileukin Diftitox, ONTAK): A New Fusion Protein Technology
Francine M. Foss
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S33-S36		 DAB389IL-2 (Denileukin Diftitox, ONTAK): Review of Clinical Trials to Date
Timothy M. Kuzel
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S37-S40		 DAB389IL-2 (Denileukin Diftitox, ONTAK): Other Potential Applications
C. Frederick LeMaistre
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S41-S44		 Historical Perspective on the Use of Retinoids in Cutaneous T-Cell Lymphoma (CTCL)
Günter Burg, Reinhard Dummer
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S45-S49		 The Treatment of Cutaneous T-Cell Lymphoma with a Novel Retinoid
Peter Heald
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
S51-S55		 Bexarotene and DAB389IL-2 (Denileukin Diftitox, ONTAK) in Treatment of Cutaneous T-Cell Lymphomas: Algorithms
Madeleine Duvic
  • Abstract
  • No Access
  • Add to Cart